The information in this section is intended for visitors outside the United States.
Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5
Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015
Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease
2014 Annual Review